Comparisons of ketoconazole, PR 969-566, PR 967-234, and PR 967-248 as antifungals in vitro and in the rat model of candidal vaginitis based on efficacy/safety profiles.
Palmer
G C
GC
Pharmaceutical Division, Pennwalt Corporation, Rochester, New York 14623.
Ordy
J M
JM
Simmons
R D
RD
Strand
J C
JC
Mullen
G B
GB
Kinsolving
C R
CR
St Georgiev
V
V
Allen
S D
SD
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002175:Candida / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D004195:Disease Models, Animal; D005260:Female; D005658:Fungi / Q000187:drug effects; D007555:Isoxazoles / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D007654:Ketoconazole / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D008826:Microbial Sensitivity Tests; D010080:Oxazoles / Q000627:therapeutic use*; D051381:Rats
D000935:Antifungal Agents; D007555:Isoxazoles; D010080:Oxazoles; C058224:PR 967234; C058223:PR 969566; C058225:PR 967248; D007654:Ketoconazole